Safety and efficacy of peptide receptor radionuclide therapy in treating high-risk patients with extensive neuroendocrine tumors

被引：0
作者：
Alsadik, S. R. [1 ]
Gnanasegaran, G. [1 ]
Chen, L. [1 ]
Toumpanakis, C. [1 ]
Caplin, M. [1 ]
Navalkissoor, S. [1 ]
机构：
[1] Royal Free Hosp, London, England
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2021年 / 33卷
关键词：
neuroendocrine tumor; net; peptide receptor radionuclide therapy prrt; 1771u-dotatate; extensive liver metastases; extensive skeletal metastases; extensive tumor burden;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
K05
引用
收藏
页码：172 / 172
页数：1
相关论文
共 50 条
  • [41] Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging
    Paganelli, Giovanni
    Sansovini, Maddalena
    Scarpi, Emanuela
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (10) : 1777 - 1778
  • [42] A single institution experience with peptide receptor radionuclide therapy (PRRT) in non-midgut neuroendocrine tumors (NETs)
    Duan, H.
    Ferri, V
    Fisher, G.
    Shaheen, S.
    Davidzon, G.
    Moradi, F.
    Nguyen, J.
    Franc, B.
    Iagaru, A.
    Mari, Aparici C.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 181 - 181
  • [43] Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging
    Giovanni Paganelli
    Maddalena Sansovini
    Emanuela Scarpi
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 1777 - 1778
  • [44] Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study
    Guo, Wei
    Wen, Xuejun
    Chen, Yuhang
    Zhao, Tianzhi
    Liu, Jia
    Tao, Yucen
    Fu, Hao
    Wang, Hongjian
    Xu, Weizhi
    Pang, Yizhen
    Zhao, Liang
    Huang, Jingxiong
    Xu, Pengfei
    Guo, Zhide
    Miao, Weibing
    Zhang, Jingjing
    Chen, Xiaoyuan
    Chen, Haojun
    ACTA PHARMACEUTICA SINICA B, 2025, 15 (02) : 707 - 721
  • [45] Real-life efficacy and toxicity of lutetium peptide receptor radionuclide therapy in patients with progressive, metastatic neuroendocrine tumors who failed at least one line of systemic treatment
    Kavan, P.
    Rho, H.
    Probst, S.
    Abikhzer, G.
    Rho, Y. S.
    Barrera, I
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 193 - 193
  • [46] Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving peptide receptor radionuclide therapy
    Mathew, Annie
    Kersting, David
    Fendler, Wolfgang P.
    Braegelmann, Johanna
    Fuhrer, Dagmar
    Lahner, Harald
    FRONTIERS IN ENDOCRINOLOGY, 2025, 16
  • [47] Patients with Advanced Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy with 177Lu-DOTATE: Data from Spanish SEPTRALU Registry
    Mitjavila, M.
    Percovich, J. C.
    Pombo Pasin, M. C.
    Bello, P.
    Arbizu, J.
    Llana, B.
    Riesco, M. C.
    Muros, M. A.
    Estenoz, J.
    Rotger, A.
    Aller, J.
    Jimenez-Fonseca, P.
    NEUROENDOCRINOLOGY, 2019, 108 : 223 - 223
  • [48] Therapy-Related Myeloid Neoplasms in Patients with Neuroendocrine Neoplasms after Peptide Receptor Radionuclide Therapy: A Systematic Review
    Sonbol, M.
    Hilal, T.
    Halfdanarson, T.
    NEUROENDOCRINOLOGY, 2020, 110 : 105 - 105
  • [49] Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
    Sabet, Amir
    Mader, Nicolai
    Bittenbring, Joerg Thomas
    Khreish, Fadi
    Gruenwald, Frank
    Biersack, Hans Jurgen
    Ezziddin, Samer
    PHARMACEUTICALS, 2021, 14 (10)
  • [50] Safety and efficacy of peptide receptor radionuclide therapy with 177 Lu-DOTA 0-Tyr 3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors
    Kobayashi, N.
    Takano, S.
    Ito, K.
    Sugiura, M.
    Ogawa, M.
    Takeda, Y.
    Okubo, N.
    Suzuki, A.
    Tokuhisa, M.
    Kaneta, T.
    Utsunomiya, D.
    Hata, M.
    Inoue, T.
    Hosono, M.
    Kinuya, S.
    Ichikawa, Y.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 149 - 149
12345